Edotecarin: Banyu/Pfizer

IDrugs

Volumn 7, Issue 2, 2004, Pages 173-177

  Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; DNA TOPOISOMERASE INHIBITOR; EDOTECARIN; MITOXANTRONE; TOPOTECAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; DNA TOPOISOMERASE; ENZYME INHIBITOR; INDOLE DERIVATIVE;

ALOPECIA; BRAIN TUMOR; BREAST TUMOR; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL TUMOR; CYTOTOXICITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ESOPHAGUS TUMOR; GRANULOCYTOPENIA; HUMAN; NEUTROPENIA; NONHUMAN; REVIEW; SOLID TUMOR; STOMACH TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; ANIMAL; ARTICLE; DRUG ANTAGONISM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBAZOLES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; INDOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2442674419     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. 171407 DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts. Giovanella B, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M SCIENCE 1989 246 4933 1046-1048
2. 237871 Banyu to test ED-749 in US/Japan. SCRIP 1997 2207 24
3. 253534 Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M, Saijo N CANCER RES 1996 56 4 789-793
4. 344277 Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Yoshinari T, Ohkubo M, Fukasawa K, Egashira S-I, Hara Y, Matsumoto M, Nakai K, Arakawa H, Morishima H, Nishimura S CANCER RES 1999 59 17 4271-4275
5. 351503 Synthesis and biological activities of NB-506 analogs: Effects of the positions of two hydroxyl groups at the indole rings. Ohkubo M, Nishimura T, Honma T, Nishimura I, Ito S, Yoshinari T, Suda H, Arakawa H, Morishima H, Nishimura S BIOORG MED CHEM LETT 1999 9 23 3307-3312
6. 369263 A phase-1 study of the novel topoisomerase-I inhibitor J-107088 administered on a multi-dose schedule. Lewis LD, Perez RP, Petros WP, Matsumoto M, Natsumeda Y, Rothenberg ML PROC AM SOC CLIN ONCOL 2000 19 Abs 688
7. 369654 Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Peck RA PROC AM SOC CLIN ONCOL 2000 19 Abs 767
8. 369867 Synthesis and biological activities of NB-506 analogs modified at the glucose group. Ohkubo M, Nishimura T, Kawamoto H, Nakano M, Honma T, Yoshinari T, Arakawa H, Suda H, Morishima H, Nishimura S BIOORG MED CHEM LETT 2000 10 5 419-422
9. 423872 Investor relations: Research and development: Pipeline. Banyu Pharmaceutical Co Ltd COMPANY WORLDWIDE WEBSITE 2001 October 02
10. 423980 Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H, Nishimura S CANCER RES 2001 61 7 2827-2832
11. 451722 Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyl-2-hydroxy) ethylamino-12,13-dihydro-13-(β-D- glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts. Cavazos CM, Keir ST, Yoshinara T, Bigner DD, Friedman HS CANCER CHEMOTHER PHARMACOL 2001 48 3 250-254
12. 451883 Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Yamada Y, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Tamura T, Kamiya Y, Saka H, Matsumoto M, Miyahara S et al PROC AM SOC CLIN ONCOL 2002 21 Abs 385
13. 452358 Phase II trials of J-107088, a non-camptothecin topoisomerase I inhibitor, in irinotecan naïve/refractory metastatic colorectal cancer. Perez RP, Hurwitz H, Nahum K, Lee J, Shiba D, Garcia M, Pipas JM, Spina MA, Matsumoto M, Natsumeda Y, Yao S-L PROC AM SOC CLIN ONCOL 2002 21 Abs 632
14. 454899 Pipeline. Banyu Pharmaceutical Co Ltd COMPANY WORLDWIDE WEBSITE 2002 April
15. 465097 Banyu to boost its sales to ¥300 billion by FY2007: Mr Nagasaka. PHARMA JPN 2002 1812 September 23 1-3
16. 467360 Banyu and Pharmacia reach agreement for development and commercialization of novel anticancer agent J-107088. Banyu Pharmaceutical Co Ltd/Pharmacia Corp PRESS RELEASE 2002 October 21
17. 485979 Plasma stability of two glycosyl indolocarbazole antitumor agents. Goossens JF, Kluza J, Vezin H, Kouach M, Briand G, Baldeyrou B, Wattez N, Bailly C BIOCHEM PHARMACOL 2003 65 1 25-34
18. 488534 Brief report of interim financial results. Banyu Pharmaceutical Co Ltd COMPANY PUBLICATION 2002 November 14
19. 492241 Phase II efficacy and tolerability study of edotecarin (J-107088) in patients with irinotecan-naïve metastatic colorectal cancer (MCRC). Nahum K, Shiba D, Padavanija P, Garcia M, Hurwitz H, Mackintosh F, Natsumeda Y, Yatsuzuka N, Locker P, Gruia G PROC AM SOC CLIN ONCOL 2003 22 Abs 1099
20. 494388 Analyst meeting - research and early development. Pfizer Inc COMPANY PRESENTATION 2003 June 17
21. 498081 In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Arakawa H, Morita M, Kodera T, Okura A, Ohkubo M, Morishima H, Nishimura S JAP J CANCER RES 1999 90 10 1163-1170
22. 510165 Pfizer Inc third-quarter 2003 performance report. Pfizer Inc PRESS RELEASE 2003 October 22
23. 510168 Second supplementary questions and answers - Pfizer Inc Earnings. Pfizer Inc PRESS RELEASE 2003 October 22
24. 510328 Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy. Husain I, Mohler JL, Seigler HF, Besterman JM CANCER RES 1994 54 2 539-546
25. 510329 Practical synthesis of a potent indolocarbazole-based, DNA topoisomerase inhibitor. Akao A, Hiraga S, Iida T, Kamatani A, Kawasaki M, Mase T, Nemoto T, Satake N, Weissman SA, Tschaen DM, Rossen K et al TETRAHEDRON 2001 57 8917-8923
26. 510330 ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport. Nakagawa R, Hara Y, Arakawa H, Nishimura S, Komatani H BIOCHEM BIOPHYS RES COMMUN 2002 299 4 669-675
27. 510331 Structure-activity relationship in O-glucuronidation of indolocarbazole analogs. Takenaga N, Ishii M, Kamei T, Yasumori T DRUG METAB DISPOS 2002 30 5 494-497
28. 510332 A rapid and sensitive liquid chromatography/negative ion tandem mass spectrometry method for the determination of an indolocarbazole in human plasma using internal standard (IS) 96-well diatomaceous earth plates for solid-liquid extraction. Wang AQ, Zeng W, Musson DG, Rogers JD, Fisher AL RAPID COMMUN MASS SPECTROM 2002 16 10 975-981
29. 513145 Human DNA topoisomerase II: Evaluation of enzyme activity in normal and neoplastic tissues. Holden JA, Rolfson DH, Wittwer CT BIOCHEMISTRY 1990 29 8 2127-2134
30. 513151 Gene expression of DNA topoisomerases I, IIα and IIβ and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Comarotti M, Capranico G, Bohm S, Oriana S, Spatti GB, Mariani L, Ballabio G, Zunino F INT J CANCER 1996 67 4 479-484
31. 513361 National Institutes of Health. COMPANY WORLDWIDE WEBSITE 2003 November 17
32. 519897 Pfizer Inc 2003 performance report. Pfizer Inc PRESS RELEASE 2004 January 22